GeoVax Labs, Inc. (GOVX)
- Previous Close
1.4700 - Open
1.4700 - Bid --
- Ask --
- Day's Range
1.3999 - 1.6299 - 52 Week Range
1.3999 - 11.5350 - Volume
37,441 - Avg. Volume
43,684 - Market Cap (intraday)
3.278M - Beta (5Y Monthly) 2.92
- PE Ratio (TTM)
-- - EPS (TTM)
-14.2900 - Earnings Date May 2, 2024 - May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
76.25
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.
www.geovax.comRecent News: GOVX
Performance Overview: GOVX
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GOVX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GOVX
Valuation Measures
Market Cap
3.28M
Enterprise Value
-3.17M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.57
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
0.12
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-82.27%
Return on Equity (ttm)
-160.47%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-25.97M
Diluted EPS (ttm)
-14.2900
Balance Sheet and Cash Flow
Total Cash (mrq)
6.45M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-16.95M